Hepatic fibrogenesis is a pathophysiological outcome of chronic liver injury hallmarked by excessive accumulation of extracellular matrix proteins. Fibrosis is a dynamic process that involves cross-talk between parenchymal cells (hepatocytes), hepatic stellate cells, sinusoidal endothelial cells and both resident and infiltrating immune cells. In this review, we focus on key cell-types that contribute to liver fibrosis, cytokines, and chemokines influencing this process and what it takes for fibrosis to regress. We discuss how mitochondria and metabolic changes in hepatic stellate cells modulate the fibrogenic process. We also briefly review how the presence of fibrosis affects development of hepatocellular carcinoma.
Impact statement
Advanced liver fibrosis results in cirrhosis, portal hypertension, and liver failure and often requires liver transplantation. Advanced liver fibrosis and cirrhosis are also major risk factors for hepatocellular carcinoma (HCC). Hepatic stellate cells (HSCs) play a pivotal role in the pathogenesis of liver fibrosis. In this review, we summarize the basic mechanisms that influence liver fibrosis development and how oxidative stress, mitochondrial dysfunction, and metabolic remodeling modulate HSC activation and indicate areas of potential therapeutic intervention.
GabeleEBrennerDARippeRA.Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci2003;
8:d69–77
5.
KisselevaTCongMPaikYScholtenDJiangCBennerCIwaisakoKMoore-MorrisTScottBTsukamotoHEvansSMDillmannWGlassCKBrennerDA.Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A2012;
109:9448–53
6.
HauffPGottwaldUOckerM.Early to phase II drugs currently under investigation for the treatment of liver fibrosis. Expert Opin Investig Drugs2015;
24:309–27
7.
MederackeIHsuCCTroegerJSHuebenerPMuXDapitoDHPradereJPSchwabeRF.Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun2013;
4:2823
8.
HendersonNCArnoldTDKatamuraYGiacominiMMRodriguezJDMcCartyJHPellicoroARaschpergerEBetsholtzCRuminskiPGGriggsDWPrinsenMJMaherJJIredaleJPLacy-HulbertAAdamsRHSheppardD.Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med2013;
19:1617–24
9.
PucheJELeeYAJiaoJAlomanCFielMIMuñozUKrausTLeeTYeeHFFriedmanSL.A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. Hepatology2013;
57:339–50
10.
ChoiSSDiehlAM.Epithelial-to-mesenchymal transitions in the liver. Hepatology2009;
50:2007–13
11.
KalluriR.EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest2009;
119:1417–9
12.
TauraKMiuraKIwaisakoKOsterreicherCHKodamaYPenz-OsterreicherMBrennerDA.Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology2010;
51:1027–36
13.
ScholtenDWeiskirchenR.Questioning the challenging role of epithelial-to-mesenchymal transition in liver injury. Hepatology2011;
53:1048–51
14.
ChuASDiazRHuiJJYangerKZongYAlpiniGStangerBZWellsRG.Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology2011;
53:1685–95
15.
MunkerSWuYLDingHGLiebeRWengHL.Can a fibrotic liver afford epithelial-mesenchymal transition?World J Gastroenterol2017;
23:4661–8
16.
ProckopDJ.Inflammation, fibrosis, and modulation of the process by mesenchymal stem/stromal cells. Matrix Biol2016;
51:7–13
17.
BucalaRSpiegelLAChesneyJHoganMCeramiA.Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med1994;
1:71–81
18.
AbeRDonnellySCPengTBucalaRMetzCN.Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol2001;
166:7556–62
19.
QuanTECowperSWuSPBockenstedtLKBucalaR.Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol2004;
36:598–606
20.
KisselevaTUchinamiHFeirtNQuintana-BustamanteOSegoviaJCSchwabeRFBrennerDA.Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol2006;
45:429–38
21.
ScholtenDReichartDPaikYHLindertJBhattacharyaJGlassCKBrennerDAKisselevaT.Migration of fibrocytes in fibrogenic liver injury. Am J Pathol2011;
179:189–98
22.
LuaILiYPappoeLSAsahinaK.Myofibroblastic conversion and regeneration of mesothelial cells in peritoneal and liver fibrosis. Am J Pathol2015;
185:3258–73
23.
MutsaersSE.Mesothelial cells: their structure, function and role in serosal repair. Respirology2002;
7:171–91
24.
AsahinaKZhouBPuWTTsukamotoH.Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. Hepatology2011;
53:983–95
25.
RinkevichYMoriTSahooDXuPXBerminghamJRWeissmanIL.Identification and prospective isolation of a mesothelial precursor lineage giving rise to smooth muscle cells and fibroblasts for mammalian internal organs, and their vasculature. Nat Cell Biol2012;
14:1251–60
26.
LiYWangJAsahinaK.Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury. Proc Natl Acad Sci U S A2013;
110:2324–9
27.
LuaILiYZagoryJAWangKSFrenchSWSévignyJAsahinaK.Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers. J Hepatol2016;
64:1137–46
28.
TangLTanakaYMarumoFSatoC.Phenotypic change in portal fibroblasts in biliary fibrosis. Liver1994;
14:76–82
29.
HerbstHFreyAHeinrichsOMilaniSBechsteinWONeuhausPSchuppanD.Heterogeneity of liver cells expressing procollagen types I and IV in vivo. Histochem Cell Biol1997;
107:399–409
30.
CassimanDLibbrechtLDesmetVDenefCRoskamsT.Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol2002;
36:200–9
31.
DesmoulièreADarbyICostaAMRaccurtMTuchweberBSommerPGabbianiG.Extracellular matrix deposition, lysyl oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic fibrosis in the rat. Lab Invest1997;
76:765–78
DranoffJAWellsRG.Portal fibroblasts: underappreciated mediators of biliary fibrosis. Hepatology2010;
51:1438–44
34.
FaustherMGoreeJRLavoieÉGrahamALSévignyJDranoffJA.Establishment and characterization of rat portal myofibroblast cell lines. PLoS One2015;
10:e0121161
35.
IwaisakoKJiangCZhangMCongMMoore-MorrisTJParkTJLiuXXuJWangPPaikYHMengFAsagiriMMurrayLAHofmannAFIidaTGlassCKBrennerDAKisselevaT.Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A2014;
111:E3297–305
MarraF.Chemokines in liver inflammation and fibrosis. Front Biosci2002;
7:d1899–914
38.
ShiZWakilAERockeyDC.Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A1997;
94:10663–8
39.
SchwabeRFBatallerRBrennerDA.Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol2003;
285:G949–58
40.
HammerichLHeymannFTackeF.Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol2011;
2011:345803
MengFWangKAoyamaTGrivennikovSIPaikYScholtenDCongMIwaisakoKLiuXZhangMOsterreicherCHStickelFLeyKBrennerDAKisselevaT.Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology2012;
143:e13
43.
KronenbergerBRudloffIBachmannMBrunnerFKapperLFilmannNWaidmannOHerrmannEPfeilschifterJZeuzemSPiiperAMühlH.Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study. BMC Med2012;
10:102
44.
QinSMaSHuangXLuDZhouYJiangH.Th22 cells are associated with hepatocellular carcinoma development and progression. Chin J Cancer Res2014;
26:135–41
45.
JiangRTanZDengLChenYXiaYGaoYWangXSunB.Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology2011;
54:900–9
46.
RadaevaSSunRPanHNHongFGaoB.Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology2004;
39:1332–42
47.
KiSHParkOZhengMMorales-IbanezOKollsJKBatallerRGaoB.Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology2010;
52:1291–300
48.
FengDWangYWangHWengHKongXMartin-MurphyBVLiYParkODooleySJuCGaoB.Acute and chronic effects of IL-22 on acetaminophen-induced liver injury. J Immunol2014;
193:2512–8
49.
KongXFengDWangHHongFBertolaAWangFSGaoB.Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology2012;
56:1150–9
50.
ZhaoJZhangZLuanYZouZSunYLiYJinLZhouCFuJGaoBFuYWangFS.Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology2014;
59:1331–42
51.
ZhangYCobleighMALianJQHuangCXBoothCJBaiXFRobekMD.A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology2011;
141:1897–906
52.
FengDKongXWengHParkOWangHDooleySGershwinMEGaoB.Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology2012;
143:188–98.e7
TanZLiuQJiangRLvLShotoSSMailletIQuesniauxVTangJZhangWSunBRyffelB.Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells. Cell Mol Immunol2018;
15:388–98
55.
MarviePLisbonneML'Helgoualc'hARauchMTurlinBPreisserLBourd-BoittinKTheretNGascanHPiquet-PellorceCSamsonM.Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med2010;
14:1726–39
56.
OoYHShettySAdamsDH.The role of chemokines in the recruitment of lymphocytes to the liver. Dig Dis2010;
28:31–44
57.
MarraFDeFrancoRGrapponeCMilaniSPastacaldiSPinzaniMRomanelliRGLaffiGGentiliniP.Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol1998;
152:423–30
58.
KarlmarkKRWeiskirchenRZimmermannHWGasslerNGinhouxFWeberCMeradMLueddeTTrautweinCTackeF.Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology2009;
50:261–74
59.
BaeckCWehrAKarlmarkKRHeymannFVucurMGasslerNHussSKlussmannSEulbergDLueddeTTrautweinCTackeF.Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut2012;
61:416–26
60.
TackeF.Targeting hepatic macrophages to treat liver diseases. J Hepatol2017;
66:1300–12
61.
KrenkelOTackeF.Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol2017;
17:306–21
62.
DooleySten DijkeP.TGF-β in progression of liver disease. Cell Tissue Res2012;
347:245–56
63.
LiLWangJYYangCQJiangW.Effect of RhoA on transforming growth factor β1-induced rat hepatic stellate cell migration. Liver Int2012;
32:1093–102
64.
RoderburgCUrbanGWBettermannKVucurMZimmermannHSchmidtSJanssenJKoppeCKnollePCastoldiMTackeFTrautweinCLueddeT.Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology2011;
53:209–18
65.
RoySBenzFVargas CardenasDVucurMGautheronJSchneiderAHellerbrandCPottierNAlderJTackeFTrautweinCRoderburgCLueddeT.miR-30c and miR-193 are a part of the TGF-β-dependent regulatory network controlling extracellular matrix genes in liver fibrosis. J Dig Dis2015;
16:513–24
66.
YanXLinZChenFZhaoXChenHNingYChenYG.Human BAMBI cooperates with Smad7 to inhibit transforming growth factor-beta signaling. J Biol Chem2009;
284:30097–104
67.
AriasMSauer-LehnenSTreptauJJanoschekNTheuerkaufIBuettnerRGressnerAMWeiskirchenR.Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterol2003;
3:29
68.
KinoshitaKIimuroYOtogawaKSaikaSInagakiYNakajimaYKawadaNFujimotoJFriedmanSLIkedaK.Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut2007;
56:706–14
69.
PinzaniMGesualdoLSabbahGMAbboudHE.Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest1989;
84:1786–93
70.
BreitkopfKGodoyPCiuclanLSingerMVDooleyS.TGF-beta/Smad signaling in the injured liver. Z Gastroenterol2006;
44:57–66
71.
KinnmanNHultcrantzRBarbuVReyCWendumDPouponRHoussetC.PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest2000;
80:697–707
72.
CzochraPKlopcicBMeyerEHerkelJGarcia-LazaroJFThieringerFSchirmacherPBiesterfeldSGallePRLohseAWKanzlerS.Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol2006;
45:419–28
73.
Borkham-KamphorstEMeurerSKVan de LeurEHaasUTihaaLWeiskirchenR.PDGF-D signaling in portal myofibroblasts and hepatic stellate cells proves identical to PDGF-B via both PDGF receptor type α and β. Cell Signal2015;
27:1305–14
74.
LuangmonkongTSurigugaSMutsaersHAMGroothuisGMMOlingaPBoersemaM.Targeting oxidative stress for the treatment of liver fibrosis. Rev Physiol Biochem Pharmacol2018;
175:71–102
75.
BedardKKrauseKH.The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev2007;
87:245–313
76.
PaikYHIwaisakoKSekiEInokuchiSSchnablBOsterreicherCHKisselevaTBrennerDA.The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology2011;
53:1730–41
77.
PaikYHKimJAoyamaTDe MinicisSBatallerRBrennerDA.Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal2014;
20:2854–72
78.
De MinicisSBrennerDA.NOX in liver fibrosis. Arch Biochem Biophys2007;
462:266–72
79.
De MinicisSSekiEPaikYHOsterreicherCHKodamaYKluweJTorozziLMiyaiKBenedettiASchwabeRFBrennerDA.Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis. Hepatology2010;
52:1420–30
80.
LanTKisselevaTBrennerDA.Deficiency of NOX1 or NOX4 prevents liver inflammation and fibrosis in mice through inhibition of hepatic stellate cell activation. PLoS One2015;
10:e0129743
81.
LiangSMaHYZhongZDharDLiuXXuJKoyamaYNishioT, KD, KarinGMccubbinRZhangCHuRYangGChenLGangulySLanTKarinMKisselevaTBrennerDA.NADPH oxidase 1 in liver macrophages promotes inflammation and tumor development in mice. Gastroenterology2019;
156:1156–72
82.
AoyamaTPaikYHWatanabeSLaleuBGagginiFFioraso-CartierLMolangoSHeitzFMerlotCSzyndralewiezCPagePBrennerDA.Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology2012;
56:2316–27
83.
JiangJXChenXSerizawaNSzyndralewiezCPagePSchröderKBrandesRPDevarajSTörökNJ.Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med2012;
53:289–96
84.
BettaiebAJiangJXSasakiYChaoTIKissZChenXTianJKatsuyamaMYabe-NishimuraCXiYSzyndralewiezCSchröderKShahABrandesRPHajFGTörökNJ.Hepatocyte nicotinamide adenine dinucleotide phosphate reduced oxidase 4 regulates stress signaling, fibrosis, and insulin sensitivity during development of steatohepatitis in mice. Gastroenterology2015;
149:468–80.e10
85.
De BleserPJXuGRomboutsKRogiersVGeertsA.Glutathione levels discriminate between oxidative stress and transforming growth factor-beta signaling in activated rat hepatic stellate cells. J Biol Chem1999;
274:33881–7
86.
BarnesJLGorinY.Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int2011;
79:944–56
87.
BalabanRSNemotoSFinkelT.Mitochondria, oxidants, and aging. Cell2005;
120:483–95
88.
GrattaglianoIRussmannSDiogoCBonfrateLOliveiraPJWangDQPortincasaP.Mitochondria in chronic liver disease. Curr Drug Targets2011;
12:879–93
YangLVennetiSNagrathD.Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng2017;
19:163–94
93.
LiJGhazwaniMLiuKHuangYChangNFanJHeFLiLBuSXieWMaXLiS.Regulation of hepatic stellate cell proliferation and activation by glutamine metabolism. PLoS One2017;
12:e0182679
94.
DuKHyunJPremontRTChoiSSMichelottiGASwiderska-SynMDaltonGDThelenERiziBSJungYDiehlAM.Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells. Gastroenterology2018;
154:1465–79.e13
95.
GarciaDShawRJ.AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell2017;
66:789–800
CaligiuriABertolaniCGuerraCTAleffiSGalastriSTrappoliereMVizzuttiFGelminiSLaffiGPinzaniMMarraF.Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology2008;
47:668–76
98.
Valfrè di BonzoLNovoECannitoSBuslettaCPaternostroCPoveroDParolaM.Angiogenesis and liver fibrogenesis. Histol Histopathol2009;
24:323–41
99.
FernándezMSemelaDBruixJColleIPinzaniMBoschJ.Angiogenesis in liver disease. J Hepatol2009;
50:604–20
100.
Sanz-CamenoPTrapero-MarugánMChaparroMJonesEAMoreno-OteroR.Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol2010;
2010:272170
101.
MarraFTackeF.Roles for chemokines in liver disease. Gastroenterology2014;
147:577–94.e1
102.
RockeyDC.Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis2001;
21:337–49
103.
AleffiSPetraiIBertolaniCParolaMColombattoSNovoEVizzuttiFAnaniaFAMilaniSRomboutsKLaffiGPinzaniMMarraF.Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology2005;
42:1339–48
104.
TauraKDe MinicisSSekiEHatanoEIwaisakoKOsterreicherCHKodamaYMiuraKIkaiIUemotoSBrennerDA.Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology2008;
135:1729–38
105.
KuklaM.Angiogenesis: a phenomenon which aggravates chronic liver disease progression. Hepatol Int2013;
7:4–12
106.
YoshijiHKuriyamaSYoshiiJIkenakaYNoguchiRHicklinDJWuYYanaseKNamisakiTYamazakiMTsujinoueHImazuHMasakiTFukuiH.Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut2003;
52:1347–54
107.
WangYQLukJMIkedaKManKChuACKanedaKFanST.Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun2004;
317:358–62
108.
StrieterRMBurdickMDGompertsBNBelperioJAKeaneMP.CXC chemokines in angiogenesis. Cytokine Growth Factor Rev2005;
16:593–609
109.
SahinHWasmuthHE.Chemokines in tissue fibrosis. Biochim Biophys Acta2013;
1832:1041–8
110.
AbbaspourNHurrellRKelishadiR.Review on iron and its importance for human health. J Res Med Sci2014;
19:164–74
111.
PhilippeMARuddellRGRammGA.Role of iron in hepatic fibrosis: one piece in the puzzle. World J Gastroenterol2007;
13:4746–54
112.
BonkovskyHL.Iron and the liver. Am J Med Sci1991;
301:32–43
113.
MehtaKJFarnaudSJSharpPA.Iron and liver fibrosis: mechanistic and clinical aspects. World J Gastroenterol2019;
25:521–38
114.
DongiovanniPFracanzaniALFargionSValentiL.Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol2011;
55:920–32
115.
LeePLBeutlerE.Regulation of hepcidin and iron-overload disease. Annu Rev Pathol2009;
4:489–515
116.
NemethETuttleMSPowelsonJVaughnMBDonovanAWardDMGanzTKaplanJ.Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science2004;
306:2090–3
117.
ZhangASXiongSTsukamotoHEnnsCA.Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is expressed predominantly in hepatocytes. Blood2004;
103:1509–14
118.
HanCYKooJHKimSHGardenghiSRivellaSStrnadPHwangSJKimSG.Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt. Nat Commun2016;
7:13817
119.
ZhangLZhouFten DijkeP.Signaling interplay between transforming growth factor-beta receptor and PI3K/AKT pathways in cancer. Trends Biochem Sci2013;
38:612–20
120.
ArndtSWackerEDornCKochASaugspierMThaslerWEHartmannABosserhoffAKHellerbrandC.Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease. Gut2015;
64:973–81
121.
ArthurMJ.Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology2002;
122:1525–8
122.
IssaRZhouXConstandinouCMFallowfieldJMillward-SadlerHGacaMDSandsESulimanITrimNKnorrAArthurMJBenyonRCIredaleJP.Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology2004;
126:1795–808
123.
ParésACaballeríaJBrugueraMTorresMRodésJ.Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol1986;
2:33–42
124.
DixonJBBhathalPSHughesNRO'BrienPE.Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology2004;
39:1647–54
125.
DesmetVJRoskamsT.Cirrhosis reversal: a duel between dogma and myth. J Hepatol2004;
40:860–7
126.
IredaleJP.Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest2007;
117:539–48
127.
WanlessIRNakashimaEShermanM.Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med2000;
124:1599–607
128.
MarcellinPGaneEButiMAfdhalNSievertWJacobsonIMWashingtonMKGermanidisGFlahertyJFAguilar SchallRBornsteinJDKitrinosKMSubramanianGMMcHutchisonJGHeathcoteEJ.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet2013;
381:468–75
129.
ChangTTLiawYFWuSSSchiffEHanKHLaiCLSafadiRLeeSSHalotaWGoodmanZChiYCZhangHHindesRIloejeUBeebeSKreterB.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology2010;
52:886–93
130.
D'AmbrosioRAghemoARumiMGRonchiGDonatoMFParadisVColomboMBedossaP.A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology2012;
56:532–43
131.
DuarteSBaberJFujiiTCoitoAJ.Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biol2015;
44-46:147–56
132.
IredaleJP.Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis2001;
21:427–36
TroegerJSMederackeIGwakGYDapitoDHMuXHsuCCPradereJPFriedmanRASchwabeRF.Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology2012;
143:1073–83.e22
LlovetJMVillanuevaALachenmayerAFinnRS.Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol2015;
12:408–24
137.
SingalAGEl-SeragHB.Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol2015;
13:2140–51
138.
FattovichGStroffoliniTZagniIDonatoF.Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology2004;
127:S35–50
139.
O'RourkeJMSagarVMShahTShettyS.Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer. World J Gastroenterol2018;
24:4436–47
140.
TrevisaniFFrigerioMSantiVGrignaschiABernardiM.Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis2010;
42:341–7
141.
FaraziPADePinhoRA.Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer2006;
6:674–87
142.
IeluzziDCovoloLDonatoFFattovichG.Progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in chronic hepatitis B patients in Italy. Dig Liver Dis2014;
46:427–32
143.
ChangMHYouSLChenCJLiuCJLeeCMLinSMChuHCWuTCYangSSKuoHSChenDS.Taiwan hepatoma study G. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst2009;
101:1348–55
144.
KimerNDahlEKGluudLLKragA.Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open2012;
2:e001313
145.
KulikLEl-SeragHB.Epidemiology and management of hepatocellular carcinoma. Gastroenterology2019;
156:477–91.e1
146.
CohenJCHortonJDHobbsHH.Human Fatty liver disease: old questions and new insights. Science2011;
332:1519–23
147.
TorresDMHarrisonSA.Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology2008;
134:1682–98
148.
TilgHMoschenAR.Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology2010;
52:1836–46
149.
MittalSEl-SeragHBSadaYHKanwalFDuanZTempleSMaySBKramerJRRichardsonPADavilaJA.Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol2016;
14:124–31.e1
150.
HagstromHNasrPEkstedtMHammarUStalPHultcrantzRKechagiasS.Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol2017;
67:1265–73
151.
AffoSYuLXSchwabeRF.The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol2017;
12:153–86
152.
BaglieriJBrennerDAKisselevaT.The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma. Int J Mol Sci2019;
20:pii: E1723
153.
HynesRO.The extracellular matrix: not just pretty fibrils. Science2009;
326:1216–9
154.
CharoIFNannizziLSmithJWChereshDA.The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin. J Cell Biol1990;
111:2795–800
155.
RahmanSPatelYMurrayJPatelKVSumathipalaRSobelMWijelathES.Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified met-integrin induced signalling pathway in endothelial cells. BMC Cell Biol2005;
6:8
156.
YuMCChenCHLiangXWangLGandhiCRFungJJLuLQianS.Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology2004;
40:1312–21
157.
ChinnaduraiRGrakouiA.B7-H4 mediates inhibition of T cell responses by activated murine hepatic stellate cells. Hepatology2010;
52:2177–85
158.
JiangGYangHRWangLWildeyGMFungJQianSLuL.Hepatic stellate cells preferentially expand allogeneic CD4+ CD25+ FoxP3+ regulatory T cells in an IL-2-dependent manner. Transplantation2008;
86:1492–502
159.
DunhamRMThapaMVelazquezVMElrodEJDenningTLPulendranBGrakouiA.Hepatic stellate cells preferentially induce Foxp3+ regulatory T cells by production of retinoic acid. J Immunol2013;
190:2009–16
160.
KrizhanovskyVYonMDickinsRAHearnSSimonJMiethingCYeeHZenderLLoweSW.Senescence of activated stellate cells limits liver fibrosis. Cell2008;
134:657–67
161.
YoshimotoSLooTMAtarashiKKandaHSatoSOyadomariSIwakuraYOshimaKMoritaHHattoriMHondaKIshikawaYHaraEOhtaniN.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature2013;
499:97–101
162.
SchnablBPurbeckCAChoiYHHagedornCHBrennerD.Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology2003;
37:653–64
163.
LujambioAAkkariLSimonJGraceDTschaharganehDFBoldenJEZhaoZThaparVJoyceJAKrizhanovskyVLoweSW.Non-cell-autonomous tumor suppression by p53. Cell2013;
153:449–60
164.
van ZijlFMairMCsiszarASchnellerDZulehnerGHuberHEferlRBeugHDolznigHMikulitsW.Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene2009;
28:4022–33
165.
AmannTBatailleFSprussTMuhlbauerMGabeleEScholmerichJKieferPBosserhoffAKHellerbrandC.Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci2009;
100:646–53
166.
FriedmanSL.Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev2008;
88:125–72
167.
CoulouarnCCorluAGlaiseDGuenonIThorgeirssonSSClementB.Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res2012;
72:2533–42
168.
BruschiFVTardelliMClaudelTTraunerM.PNPLA3 expression and its impact on the liver: current perspectives. Hepat Med2017;
9:55–66
169.
HuangYHeSLiJZSeoYKOsborneTFCohenJCHobbsHH.A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A2010;
107:7892–7
170.
PingitorePRomeoS.The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids2019;
1864:900–6
171.
RomeoSKozlitinaJXingCPertsemlidisACoxDPennacchioLABoerwinkleECohenJCHobbsHH.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet2008;
40:1461–5
172.
LiuYLPatmanGLLeathartJBPiguetACBurtADDufourJFDayCPDalyAKReevesHLAnsteeQM.Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol2014;
61:75–81
173.
BurzaMAPirazziCMaglioCSjoholmKMancinaRMSvenssonPAJacobsonPAdielsMBaroniMGBorenJGinanni CorradiniSMontalciniTSjostromLCarlssonLMRomeoS.PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis2012;
44:1037–41
174.
TrepoERomeoSZucman-RossiJNahonP.PNPLA3 gene in liver diseases. J Hepatol2016;
65:399–412
175.
BasantaniMKSitnickMTCaiLBrennerDSGardnerNPLiJZSchoiswohlGYangKKumariMGrossRWZechnerRKershawEE.Pnpla3/adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res2011;
52:318–29
176.
ChenWChangBLiLChanL.Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology2010;
52:1134–42
177.
BasuRaySWangYSmagrisECohenJCHobbsHH.Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A2019;
116:9521–6
178.
LindenDAhnmarkAPingitorePCiociolaEAhlstedtIAndreassonACSasidharanKMadeyski-BengtsonKZurekMMancinaRMLindblomABjursellMBottcherGStahlmanMBohloolyYMHaynesWGCarlssonBGrahamMLeeRMurraySValentiLBhanotSAkerbladPRomeoS.Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Mol Metab2019;
22:49–61
179.
PirazziCValentiLMottaBMPingitorePHedfalkKMancinaRMBurzaMAIndiveriCFerroYMontalciniTMaglioCDongiovanniPFargionSRamettaRPujiaAAnderssonLGhosalSLevinMWiklundOIacovinoMBorenJRomeoS.PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet2014;
23:4077–85
180.
MondulAMancinaRMMerloADongiovanniPRamettaRMontalciniTValentiLAlbanesDRomeoS.PNPLA3 I148M variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity. J Nutr2015;
145:1687–91
181.
KovarovaMKonigsrainerIKonigsrainerAMachicaoFHaringHUSchleicherEPeterA.The genetic variant I148M in PNPLA3 is associated with increased hepatic Retinyl-Palmitate storage in humans. J Clin Endocrinol Metab2015;
100:E1568–74
182.
LeeYSJeongWI.Retinoic acids and hepatic stellate cells in liver disease. J Gastroenterol Hepatol2012;
27(Suppl 2):75–9
183.
FieldsALSopranoDRSopranoKJ.Retinoids in biological control and cancer. J Cell Biochem2007;
102:886–98
184.
ChavesGVPereiraSESaboyaCJSpitzDRodriguesCSRamalhoA.Association between liver vitamin a reserves and severity of nonalcoholic fatty liver disease in the class III obese following bariatric surgery. Obes Surg2014;
24:219–24
185.
ChenG.The link between hepatic vitamin a metabolism and nonalcoholic fatty liver disease. Curr Drug Targets2015;
16:1281–92
186.
PingitorePDongiovanniPMottaBMMeroniMLeporeSMMancinaRMPelusiSRussoCCaddeoARossiGMontalciniTPujiaAWiklundOValentiLRomeoS.PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Hum Mol Genet2016;
25:5212–22
187.
BruschiFVClaudelTTardelliMCaligiuriAStulnigTMMarraFTraunerM.The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology2017;
65:1875–90
188.
MinHKSookoianSPirolaCJChengJMirshahiFSanyalAJ.Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in huh-7 hepatoma cells. Am J Physiol Gastrointest Liver Physiol2014;
307:G66–76
